Published in Mol Med Today on July 01, 1997
Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med (2009) 1.03
Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A (2004) 0.95
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis. J Neurol (2012) 0.81
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 3.67
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol (2000) 2.07
P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 1.92
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86
MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology (1999) 1.80
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Improved diffusion-weighted single-shot echo-planar imaging (EPI) in stroke using sensitivity encoding (SENSE). Magn Reson Med (2001) 1.69
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology (1999) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Diffusion-weighted imaging of patients with subacute cerebral ischemia: comparison with conventional and contrast-enhanced MR imaging. AJNR Am J Neuroradiol (2000) 1.49
The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol (2001) 1.43
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
[Physical trauma and multiple sclerosis]. Nervenarzt (1997) 1.38
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34
Platelet activating factor (PAF) induces the oxidative burst in macrophages. Int J Immunopharmacol (1983) 1.31
Molecular mechanisms of microglial activation. Adv Neuroimmunol (1996) 1.29
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. Mult Scler (2012) 1.24
Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol (1995) 1.19
Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med (2000) 1.19
Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol (1999) 1.16
Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol (1983) 1.16
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 1.14
Production and characterization of monoclonal antibodies to the extracellular domain of P0. J Neurosci Res (1993) 1.13
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler (2010) 1.11
Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol (1983) 1.10
Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Int J Dev Neurosci (1995) 1.08
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 1.07
Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol (1993) 1.07
T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci (1997) 1.07
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain (1998) 1.07
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 1.06
The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci (1999) 1.06
Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol (1997) 1.06
Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol (2009) 1.05
Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke (2000) 1.05
Blockade of chemokine signaling in patients with multiple sclerosis. Neurology (2006) 1.05
Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci (2000) 1.05
Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology (1999) 1.04
Quantitative studies of the secretion of complement component C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release. Eur J Immunol (1982) 1.04
ADEM: distinct disease or part of the MS spectrum? Neurology (2001) 1.03
Phenotype-genotype correlations in a CMT2B family with refined 3q13-q22 locus. Neurology (2000) 1.03
Ulcero-mutilating neuropathy in an Austrian kinship without linkage to hereditary motor and sensory neuropathy IIB and hereditary sensory neuropathy I loci. Neurology (2000) 1.02
Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain (2001) 1.02
Differential expression of matrix metalloproteinases in bacterial meningitis. Brain (1999) 1.02
Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77. J Immunol (1983) 1.01
Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol (1993) 1.01
Peripheral facial palsy: etiology, diagnosis and treatment. Eur Neurol (1999) 1.00
MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol (1996) 0.99
Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol (1998) 0.99
Cloning, sequencing and molecular analysis of the Campylobacter jejuni groESL bicistronic operon. Microbiology (1999) 0.99
Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol (1992) 0.99
The Bradykinesia Akinesia Incoordination Test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord (2000) 0.98
Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol (1999) 0.97
Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol (1995) 0.96
The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol (1996) 0.95
Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve (1996) 0.95
Suppression of experimental autoimmune neuritis by leflunomide. Brain (2001) 0.93
Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol (1999) 0.93
Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain (1998) 0.93
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology (2001) 0.93
Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol (1996) 0.93
Phenotypic and genotypic heterogeneity in hereditary motor neuronopathy type V: a clinical, electrophysiological and genetic study. Brain (2000) 0.92
Stimulation of the scavenger receptor on monocytes-macrophages evokes release of arachidonic acid metabolites and reduced oxygen species. Lab Invest (1986) 0.92
A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol (2001) 0.92
Pravastatin-associated inflammatory myopathy. N Engl J Med (1992) 0.92
In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain (1996) 0.91
Comparison of second lumbrical and interosseus latencies with standard measures of median nerve function across the carpal tunnel: a prospective study of 450 hands. J Neurol (2000) 0.91
Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 0.91
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]. Nervenarzt (2005) 0.91
Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol (1997) 0.90
Diffusion-weighted MR imaging of the spinal cord. AJNR Am J Neuroradiol (2000) 0.90
Cloning and expression of the dnaK gene of Campylobacter jejuni and antigenicity of heat shock protein 70. Infect Immun (1999) 0.90
Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Brain (1996) 0.90
Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol (1995) 0.90
Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction. J Neuroimmunol (1996) 0.89
The ClpB protein from Campylobacter jejuni: molecular characterization of the encoding gene and antigenicity of the recombinant protein. Gene (1999) 0.89
T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain (2000) 0.88
Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. Am J Pathol (1997) 0.88
H2O2 and nitric oxide-mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts. J Neuropathol Exp Neurol (1996) 0.88
Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat. Brain (1989) 0.88
Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. J Neuroimmunol (2001) 0.88
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol (1996) 0.87
Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol (2007) 0.87
Stimulation of prostaglandin E and thromboxane synthesis in macrophages by purified C3b. J Immunol (1983) 0.87
Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol (2000) 0.87
Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve (1995) 0.87
Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol (2000) 0.87